Melanoma Drug's eye impact revealed in new study
NCT ID NCT07427953
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at 14 adults with melanoma who were taking a combination of BRAF and MEK inhibitor drugs. The goal was to understand how these drugs can affect the retina, the light-sensitive part of the eye. Researchers used eye exams and special imaging to track changes over time. The findings help doctors better recognize and manage these eye side effects during treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DRUG-INDUCED RETINOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Institute of Oncology Ljubljana
Ljubljana, 1000, Slovenia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can two immune boosters beat advanced melanoma?
- Drug duo takes on rare head and neck tumors
- Experimental cancer therapy targets tough tumors with radioactive precision
- Keytruda immune response trial aims to unlock cancer clues
- Experimental combo aims to supercharge cancer immunotherapy
- AI-Designed mRNA vaccine takes on advanced tumors in first human test